# NOTICE TO SHAREHOLDERS For the Three Months Ended March 31, 2021 (Unaudited and Expressed in US Dollars)

POET TECHNOLOGIES INC.

ONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION expressed in US Dollars)		March 31, 2021	D	Audited ecember 31, 2020
Assets				
Current Cash and cash equivalents (Note 2)	\$	23,472,255	\$	6,872,894
Prepaids and other current assets (Note 4)	Ψ	1,092,016	Ψ	618,717
		24,564,271		7,491,611
Property and equipment (Note 5)		3,070,871		3,185,754
Patents and licenses (Note 6)		421,682		438,677
Right of use assets (Note 7)		472,396		520,686
	\$	28,529,220	\$	11,636,728
Liabilities				
Current				
Accounts payable and accrued liabilities (Note 8)	\$	2,613,155	\$	1,730,36
Lease liability (Note 7)		189,723		172,949
Convertible debentures (Note 9)		1,169,512		3,341,246
Covid-19 government support loans (Note 20)		171,185		147,841
		4,143,575		5,392,397
Non-current covid-19 government support loans (Note 20)		47,402		70,310
Non-current Lease liability (Note 7)		300,952		359,048
		4,491,929		5,821,755
Shareholders' Equity				
Share capital (Note 10(b))		135,689,974		114,586,260
Equity component of convertible debentures (Note 9)		192,051		565,12
Warrants and compensation options (Note 11)		7,819,345		5,557,002
Contributed surplus (Note 12)		43,721,782		44,407,679
Accumulated other comprehensive loss		(1,969,564)		(1,983,212
Deficit		(161,416,297)	(	(157,317,87
		24,037,291		5,814,973
	\$	28,529,220	\$	11,636,728

Commitments and contingencies (Note 14)

On behalf of the Board of Directors

Director

# CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND DEFICIT (Expressed in US Dollars)

	Three Months Ended March 31,		
	2021 2020		
Operating expenses Selling, marketing and administration (Note 19) Research and development (Note 19)	\$ 2,328,432 \$ 1,708,872 1,542,718 1,543,571		
Operating expenses Interest expense (Notes 7 and 9) Other income, including interest	<b>3,871,150</b> 3,252,443 <b>234,579</b> 216,684 <b>(7,309)</b> (1,362)		
Net loss	<b>(4,098,420)</b> (3,467,765)		
Deficit, beginning of period	<b>(157,317,877)</b> (139,148,807)		
Net loss	<b>(4,098,420)</b> (3,467,765)		
Deficit, end of period	<b>\$(161,416,297)</b> \$(142,616,572)		
Basic and diluted net loss per share (Note 13)	<b>\$ (0.01)</b> \$ (0.01)		

# CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Expressed in US Dollars)

(Expressed in US Dollars)		onths Ended arch 31,
	2021	2020
Net loss	\$ (4,098,420)	\$ (3,467,765)
Other comprehensive income - net of income taxes Exchange differences on translating foreign operations	13,648	101,704
Comprehensive loss	\$ (4,084,772)	\$ (3,366,061)

# CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Expressed in US Dollars)

Reginn   Belance   S114,586,260 \$   \$12,144,172   Reginn   Belance   S114,586,260 \$   \$12,144,172   Runds from the exercise of warrants   \$1,244,172   \$1,264   \$1,	For the Three Months Ended March 31,	2021	2020
Beginning balance         \$114,586,280 s 112,144,172           Funds from the exercise of warrants exercised         6,284,890 s 23,675           Conversion of convertible debentures         2,415,006 s 293,675           Fair value a ssigned to warrants issued upon the conversion of convertible debentures         (813,345) (212,1468) (121,468) (12	Share Capital		
Funds from the exercise of warrants   \$,284,890   \$-7   Fair value assigned to warrants exercised   \$,261,206   \$-3,245,409		\$ 114,586,260	\$ 112,144,172
Fair Value assigned to warrants exercised         2,445,409         293,675           Conversion of convertible debentures         (819,345,409)         293,675           Fair Value of warrants issued upon the conversion of convertible debentures         (819,345)         (121,468)           Funds from the exercise of stock options exercised         1,870,261         177,281           Funds from common shares issued on private placement         11,815,595         -           Fair value of warrants issued on private placement         (3,766,007)         -           Fair value of hower warrants issued as share issue costs         (288,197)         -           Fair value of broker warrants issued as share issue costs         565,121         627,511           Fair value of broker warrants issued as share issue costs         565,121         627,511           Fair value of equity component related to conversion of convertible debentures         565,121         627,511           Beginning balance         5,557,002         8,525,558           Ber value of expired compensation options issued to brokers         -         479,204           Fair value of warrants issued as share issue costs         819,345         121,468           Fair value of warrants issued as share issue costs         819,345         121,468           Fair value of warrants issued as share issue costs         819,34			· · · · · ·
Conversion of convertible debentures         2,345,409         293,675           Fair value of warrants issued upon the conversion of convertible debentures         (819,345)         (121,468)           Funds from the exercise of stock options         2,192,936         162,258           Fair value assigned to stock options exercised         1,815,595		, ,	=
Fair value of warrants issued upon the conversion of convertible debentures         (819,345 (22.84 c.228 f.23) (22.936 f.22.85 f.23) (22.936 f.22.85 f.23) (22.936 f.22.85 f.23) (22.936 f.22.85 f.23) (23.936			293.675
Funds from the exercise of stock options   2,192,936   162,258   581 eri value assigned to stock options exercised   1,870,261   171,281   171,2			
Fair value assigned to stock options exercised Funds from common shares issued on private placement 11,815,995 (3,766,007)         17. (261,007)			
Funds from common shares issued on private placement   11,815,595   Fair value of warrants issued on private placement   (1,143,034)   Fair value of broker warrants issued as share issue costs   (1,143,034)   Fair value of broker warrants issued as share issue costs   (288,197)   Fair value of broker warrants issued as share issue costs   (288,197)   Fair value of broker warrants issued as share issue costs   (373,070)   (51,249,181)			
Fair value of warrants issued on private placement         (3,766,007) (1,143,034) - (288,197)         -           Share issue costs         (1,143,034) - (288,197)         -           March 31,         135,689,974         112,649,918           Equity Component of Convertible Debentures         565,121 (57,511 (57,288)         627,511 (57,288)           March 31,         192,051 (57,288)         565,121 (57,288)           March 31,         192,051 (57,288)         5,557,002 (57,288)           March 31,         192,051 (77,204)         8,625,358           Fair value of expired compensation options issued to brokers         1,93,45 (27,204)         121,468           Fair value of warrants issued upon the conversion of convertible debentures         3,945 (21,206)         121,468           Fair value of warrants issued as share issue costs         28,197 (2,611,206)         -           Fair value of broker warrants issued as share issue costs         28,197 (2,611,206)         -           Fair value of warrants issued on private placement         3,766,007 (2,611,206)         -           March 31,         7,819,345 (3,622)         8,167,622           Contributed Surplus         820,538 (76,783)         7,76,783           Fair value of stock options exercised         (1,870,261)         (1,771,281)           Fair value of stock options exercised			-
Share issue costs         (1,143,034) (288,197)         -           Fair value of broker warrants issued as share issue costs         (288,197)         -           March 31,         135,689,974         112,649,918           Equity Component of Convertible Debentures         565,121 (373,070)         627,511           Fair value of equity component related to conversion of convertible debentures         565,121 (373,070)         627,511           March 31,         192,051 (51,288)         576,223           Warrants         Beginning balance         5,557,002 (479,204)         8,525,368           Fair value of expired compensation options issued to brokers         - (479,204)         6479,204           Fair value of warrants issued upon the conversion of convertible debentures         819,345 (211,268)         121,468           Fair value of broker warrants issued as share issue costs         288,197 (211,268)         -           Fair value of broker warrants issued as share issue costs         288,197 (211,268)         -           Fair value of broker warrants issued on private placement         3,766,007 (211,268)         -           March 31,         7,819,345 (211,268)         8,767,822           Contributed Surplus         820,538 (211,268)         7,67,83           Stock-based compensation         820,538 (211,268)         7,67,83			_
Fair value of broker warrants issued as share issue costs         (288,197)         -           March 31.         135,689,974         112,649,918           Equity Component of Convertible Debentures         565,121         627,511           Beginning balance         565,121         627,511           Fair value of equity component related to conversion of convertible debentures         (373,070)         (51,288)           Warrants         889inning balance         5,557,002         8,525,358           Fair value of expired compensation options issued to brokers         -         (479,204)           Fair value of warrants issued upon the conversion of convertible debentures         819,345         121,468           Fair value of warrants issued as share issue costs         819,345         121,468           Fair value of warrants issued as share issue costs         288,197         -           Fair value of warrants issued on private placement         7,819,345         81,676,622           March 31,         7,819,345         81,676,622           Contributed Surplus         820,538         776,783           Beginning balance         44,407,679         38,799,337           Stock-based compensation         820,538         776,783           Fair value of stock options exercised         (1,787),261         (1,781)			
March 31,         135,689,974         112,649,918           Equity Component of Convertible Debentures         565,121         627,511           Eginning balance         565,121         627,511           Fair value of equity component related to conversion of convertible debentures         565,121         627,512           March 31,         192,051         576,223           Warrants         Beginning balance         5,557,002         8,525,358           Fair value of expired compensation options issued to brokers         -         (479,204)           Fair value of expired compensation options issued to brokers         -         (479,204)           Fair value of expired compensation options issued to brokers         -         (479,204)           Fair value of expired compensation and compensation variants exercised         (2,611,206)         -           Fair value of broker warrants issued as share issue costs         288,197         -           Fair value of broker warrants issued as share issue costs         819,345         8,167,622           Contributed Surplus         820,538         8,766,007         -           Beginning balance         44,407,679         38,799,337         -         476,728           Stock-based compensation         820,538         776,783         -         479,204			
Equity Component of Convertible Debentures         565,121 (373,070)         627,511 (51,288)           Beginning balance         365,121 (373,070)         (51,288)           March 31,         192,051         576,223           Warrants         5,557,002 (479,204)         8,525,358           Beginning balance         5,557,002 (479,204)         8,525,358           Fair value of expired compensation options issued to brokers         - (479,204)         4,126           Fair value of warrants issued upon the conversion of convertible debentures         819,345 (2611,206)         -           Fair value of warrants issued as share issue costs         288,197 (-         -           Fair value of broker warrants issued as share issue costs         288,197 (-         -           Fair value of warrants issued on private placement         3,766,007 (-         -           March 31,         7,819,345 (-         8,167,622           Contributed Surplus         44,407,679 (-         38,799,337           Beginning balance         44,407,679 (-         38,799,337           Stock-based compensation         820,538 (-         776,783           Fair value of stock options exercised         (1,870,261) (-         (17,1281)           Fair value of expired warrants (-         363,826 (-         (6,011)           <			
Beginning balance         565,121         627,511           Fair value of equity component related to conversion of convertible debentures         (373,070)         (51,288)           March 31,         192,051         576,223           Warrants         5,557,002         8,525,358           Beginning balance         -         (479,204)           Fair value of expired compensation options issued to brokers         -         (479,204)           Fair value of warrants issued upon the conversion of convertible debentures         819,345         121,468           Fair value of broker warrants issued as share issue costs         288,197         -           Fair value of warrants issued as share issue costs         288,197         -           Fair value of warrants issued as share issue costs         288,197         -           Fair value of warrants issued as share issue costs         288,197         -           Fair value of warrants issued on private placement         7,819,345         8,167,622           Contributed Surplus         820,538         776,783           Fair value of stock options exercised         (1,870,261)         (1,77,281)           Fair value of expired warrants         -         479,204           Fair value of stock options exercised         (1,983,212)         (1,908,716) <td< td=""><td>March 31,</td><td>135,689,974</td><td>112,649,918</td></td<>	March 31,	135,689,974	112,649,918
Fair value of equity component related to conversion of convertible debentures         (373,070)         (51,288)           March 31,         192,051         576,223           Warrants         5,557,002         8,525,358           Fair value of expired compensation options issued to brokers         -         (479,204)           Fair value of warrants issued upon the conversion of convertible debentures         819,345         121,468           Fair value assigned to warrants and compensation warrants exercised         (2,611,206)         -           Fair value of broker warrants issued as share issue costs         288,197         -           Fair value of warrants issued on private placement         3,766,007         -           March 31,         7,819,345         8,167,622           Contributed Surplus         820,538         76,782           Beginning balance         44,407,679         38,799,337           Stock-based compensation         820,538         76,783           Fair value of stock options exercised         (1,870,261)         (171,281)           Fair value of expired warrants         -         479,204           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Co			
March 31,         192,051         576,223           Warrants         Seginning balance         5,557,002         8,525,358           Fair value of expired compensation options issued to brokers         - (479,204)           Fair value of warrants issued upon the conversion of convertible debentures         819,345         121,468           Fair value assigned to warrants issued as share issue costs         288,197         -           Fair value of broker warrants issued as share issue costs         288,197         -           Fair value of warrants issued on private placement         3,766,007         -           March 31,         7,819,345         8,167,622           Contributed Surplus         44,407,679         38,799,337           Beginning balance         44,407,679         38,799,337           Stair value of stock options exercised         (1,870,261)         (171,281)           Fair value of stock options exercised         1,870,261         (171,281)           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Comprehensive Loss         8eginning balance         (1,983,212)         (1,908,715)           Other comprehensive income attributable to common shareholders - translation adjustment			
Warrants           Beginning balance         5,557,002         8,525,358           Fair value of expired compensation options issued to brokers         - (479,204)           Fair value of warrants issued upon the conversion of convertible debentures         819,345         121,468           Fair value assigned to warrants issued as share issue costs         288,197         -           Fair value of broker warrants issued as share issue costs         288,197         -           Fair value of warrants issued on private placement         3,766,007         -           March 31,         7,819,345         8,167,622           Contributed Surplus         44,407,679         38,799,337           Beginning balance         44,407,679         38,799,337           Stock-based compensation         820,538         76,783           Fair value of stock options exercised         (1,870,261)         (171,281)           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Comprehensive Loss         [1,983,212]         (1,908,715)           Beginning balance         (1,986,564)         (1,807,011)           Other comprehensive income attributable to common shareholders - translation adjustment         13,	Fair value of equity component related to conversion of convertible debentures	(373,070)	(51,288)
Beginning balance         5,557,002         8,525,358           Fair value of expired compensation options issued to brokers         -         (479,204)           Fair value of expired compensation warrants issued upon the convertible debentures         819,345         121,468           Fair value of warrants issued own private placement         (2,611,206)         -           Fair value of broker warrants issued as share issue costs         288,197         -           Fair value of warrants issued on private placement         3,766,007         -           March 31,         7,819,345         8,167,622           Contributed Surplus         44,407,679         38,799,337           Stock-based compensation         820,533         776,783           Fair value of stock options exercised         (1,870,261)         (171,281)           Fair value of expired warrants         -         479,204           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Comprehensive Loss         (1,983,212)         (1,908,715)           Beginning balance         (1,983,212)         (1,908,715)           Other comprehensive income attributable to common shareholders - translation adjustment         13,648         101,704	March 31,	192,051	576,223
Fair value of expired compensation options issued to brokers         - (479,204)           Fair value of warrants issued upon the conversion of convertible debentures         819,345 121,468           Fair value assigned to warrants and compensation warrants exercised         (2,611,206) -           Fair value of broker warrants issued as share issue costs         288,197 -           Fair value of warrants issued on private placement         3,766,007 -           March 31,         7,819,345 8,167,622           Contributed Surplus         44,407,679 38,799,337           Beginning balance         44,407,679 42,003           Stock-based compensation         820,538 776,783           Fair value of stock options exercised         (1,870,261) (171,281)           Fair value of expired warrants         - 479,204           Fair value of expired warrants         - (8,08,20)           Fair value of expired warrants         - (9,08,21)           March 31,         43,721,782           Other comprehensive Loss         (1,983,212) <tr< td=""><td></td><td></td><td></td></tr<>			
Fair value of warrants issued upon the conversion of convertible debentures         819,345 (2,611,206) (2		5,557,002	
Fair value assigned to warrants and compensation warrants exercised       (2,611,206)       -         Fair value of broker warrants issued as share issue costs       288,197       -         Fair value of warrants issued on private placement       3,766,007       -         March 31,       7,819,345       8,167,622         Contributed Surplus       44,407,679       38,799,337         Beginning balance       44,407,679       38,799,337         Stock-based compensation       820,538       776,783         Fair value of stock options exercised       (1,870,261)       (171,281)         Fair value of expired warrants       -       479,204         Fair value effect of conversion of convertible debentures       363,826       (6,011)         March 31,       43,721,782       39,878,032         Accumulated Other Comprehensive Loss       (1,983,212)       (1,908,715)         Beginning balance       (1,983,212)       (1,908,715)         Other comprehensive income attributable to common shareholders - translation adjustment       13,648       101,704         March 31,       (1,969,564)       (1,807,011)         Deficit       (1,969,564)       (1,807,011)         Deficit       (1,969,420)       (3,467,765)         March 31,       (1,61,416,297)		=	(479,204)
Fair value of broker warrants issued as share issue costs         288,197 3,766,007         -           Fair value of warrants issued on private placement         3,766,007         -           March 31,         7,819,345         8,167,622           Contributed Surplus         8eginning balance         44,407,679         38,799,337           Stock-based compensation         820,538         776,783         711,281           Fair value of stock options exercised         (1,870,261)         (171,281)           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Comprehensive Loss         (1,983,212)         (1,908,715)           Deficit         (1,969,564)         (1,807,011)           Deficit         8eginning balance         (157,317,877)         (139,148,807)           Net loss         (4,098,420)         (3,467,765)           March 31,         (161,416,297)         (142,616,572)		819,345	121,468
Fair value of warrants issued on private placement       3,766,007       -         March 31,       7,819,345       8,167,622         Contributed Surplus       8eginning balance       44,407,679       38,799,337         Stock-based compensation       820,538       776,783       76,783       76,783       76,783       76,783       776,783       76,783       776,783       76,783       776,783 <td></td> <td>(2,611,206)</td> <td>-</td>		(2,611,206)	-
March 31,         7,819,345         8,167,622           Contributed Surplus         Beginning balance         44,407,679         38,799,337           Stock-based compensation         820,538         776,783           Fair value of stock options exercised         (1,870,261)         (171,281)           Fair value effect of expired warrants         -         479,204           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Comprehensive Loss         (1,983,212)         (1,908,715)           Other comprehensive income attributable to common shareholders - translation adjustment         13,648         101,704           March 31,         (1,969,564)         (1,807,011)           Deficit         (157,317,877)         (139,148,807)           Net loss         (4,098,420)         (3,467,765)           March 31,         (161,416,297)         (142,616,572)	Fair value of broker warrants issued as share issue costs	288,197	=
Contributed Surplus           Beginning balance         44,407,679         38,799,337           Stock-based compensation         820,538         776,783           Fair value of stock options exercised         (1,870,261)         (171,281)           Fair value of expired warrants         -         479,204           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Comprehensive Loss         (1,983,212)         (1,908,715)           Beginning balance         (1,983,212)         (1,908,715)           Other comprehensive income attributable to common shareholders - translation adjustment         13,648         101,704           March 31,         (1,969,564)         (1,807,011)           Deficit         Eginning balance         (157,317,877)         (139,148,807)           Net loss         (4,098,420)         (3,467,765)           March 31,         (161,416,297)         (142,616,572)	Fair value of warrants issued on private placement	3,766,007	-
Beginning balance       44,407,679       38,799,337         Stock-based compensation       820,538       776,783         Fair value of stock options exercised       (1,870,261)       (171,281)         Fair value effect of conversion of convertible debentures       - 479,204         Fair value effect of conversion of convertible debentures       363,826       (6,011)         March 31,       43,721,782       39,878,032         Accumulated Other Comprehensive Loss       (1,983,212)       (1,908,715)         Other comprehensive income attributable to common shareholders - translation adjustment       13,648       101,704         March 31,       (1,969,564)       (1,807,011)         Deficit       (157,317,877)       (139,148,807)         Net loss       (4,098,420)       (3,467,765)         March 31,       (161,416,297)       (142,616,572)	March 31,	7,819,345	8,167,622
Stock-based compensation         820,538         776,783           Fair value of stock options exercised         (1,870,261)         (171,281)           Fair value of expired warrants         -         479,204           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Comprehensive Loss         (1,983,212)         (1,908,715)           Other comprehensive income attributable to common shareholders - translation adjustment         13,648         101,704           March 31,         (1,969,564)         (1,807,011)           Deficit         8eginning balance         (157,317,877)         (139,148,807)           Net loss         (4,098,420)         (3,467,765)           March 31,         (161,416,297)         (142,616,572)	Contributed Surplus		_
Stock-based compensation         820,538         776,783           Fair value of stock options exercised         (1,870,261)         (171,281)           Fair value of expired warrants         -         479,204           Fair value effect of conversion of convertible debentures         363,826         (6,011)           March 31,         43,721,782         39,878,032           Accumulated Other Comprehensive Loss         (1,983,212)         (1,908,715)           Other comprehensive income attributable to common shareholders - translation adjustment         13,648         101,704           March 31,         (1,969,564)         (1,807,011)           Deficit         8eginning balance         (157,317,877)         (139,148,807)           Net loss         (4,098,420)         (3,467,765)           March 31,         (161,416,297)         (142,616,572)	Beginning balance	44,407,679	38,799,337
Fair value of stock options exercised       (1,870,261)       (171,281)         Fair value of expired warrants       -       479,204         Fair value effect of conversion of convertible debentures       363,826       (6,011)         March 31,       43,721,782       39,878,032         Accumulated Other Comprehensive Loss       (1,983,212)       (1,908,715)         Defice comprehensive income attributable to common shareholders - translation adjustment       13,648       101,704         March 31,       (1,969,564)       (1,807,011)         Deficit       8eginning balance       (157,317,877)       (139,148,807)         Net loss       (4,098,420)       (3,467,765)         March 31,       (161,416,297)       (142,616,572)		820,538	776,783
Fair value of expired warrants Fair value effect of conversion of convertible debentures  363,826 (6,011)  March 31,  43,721,782 39,878,032  Accumulated Other Comprehensive Loss Beginning balance Other comprehensive income attributable to common shareholders - translation adjustment  March 31,  (1,969,564) (1,807,011)  Deficit Beginning balance Net loss  March 31,  (157,317,877) (139,148,807) (4,098,420) (3,467,765)  March 31,  (161,416,297) (142,616,572)		(1,870,261)	(171,281)
March 31,  Accumulated Other Comprehensive Loss Beginning balance Other comprehensive income attributable to common shareholders - translation adjustment  March 31,  (1,983,212) (1,908,715) (1,908,715) (1,969,564) (1,807,011)  Deficit Beginning balance Net loss  (157,317,877) (139,148,807) (4,098,420) (3,467,765)  March 31,  (161,416,297) (142,616,572)		• • • •	
Accumulated Other Comprehensive Loss         Beginning balance       (1,983,212)       (1,908,715)         Other comprehensive income attributable to common shareholders - translation adjustment       13,648       101,704         March 31,       (1,969,564)       (1,807,011)         Deficit       (157,317,877)       (139,148,807)         Net loss       (4,098,420)       (3,467,765)         March 31,       (161,416,297)       (142,616,572)		363,826	(6,011)
Beginning balance       (1,983,212)       (1,908,715)         Other comprehensive income attributable to common shareholders - translation adjustment       13,648       101,704         March 31,       (1,969,564)       (1,807,011)         Deficit       (157,317,877)       (139,148,807)         Net loss       (4,098,420)       (3,467,765)         March 31,       (161,416,297)       (142,616,572)	March 31,	43,721,782	39,878,032
Beginning balance       (1,983,212)       (1,908,715)         Other comprehensive income attributable to common shareholders - translation adjustment       13,648       101,704         March 31,       (1,969,564)       (1,807,011)         Deficit       (157,317,877)       (139,148,807)         Net loss       (4,098,420)       (3,467,765)         March 31,       (161,416,297)       (142,616,572)	Accumulated Other Comprehensive Loss		
Other comprehensive income attributable to common shareholders - translation adjustment       13,648       101,704         March 31,       (1,969,564)       (1,807,011)         Deficit       (157,317,877)       (139,148,807)         Net loss       (4,098,420)       (3,467,765)         March 31,       (161,416,297)       (142,616,572)		(1,983,212)	(1,908,715)
Deficit         Beginning balance       (157,317,877) (139,148,807)         Net loss       (4,098,420) (3,467,765)         March 31,       (161,416,297) (142,616,572)			
Beginning balance       (157,317,877) (139,148,807)         Net loss       (4,098,420) (3,467,765)         March 31,       (161,416,297) (142,616,572)	March 31,	(1,969,564)	(1,807,011)
Net loss (4,098,420) (3,467,765)  March 31, (161,416,297) (142,616,572)	Deficit		
March 31, (161,416,297) (142,616,572)			
	Net loss	(4,098,420)	(3,467,765)
Total shareholders' equity \$ 24,037,291 \$ 16,848,212	March 31,	(161,416,297)	(142,616,572)
	Total shareholders' equity	\$ 24,037,291	\$ 16,848,212

# CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Expressed in US Dollars)

For the Three Months Ended March 31,	2021	2020
CASH (USED IN) PROVIDED BY:		
OPERATING ACTIVITIES		
Net loss Adjustments for:	\$ (4,098,420)	\$ (3,467,765)
Depreciation of property and equipment (Note 5) Amortization of patents and licenses (Note 6)	188,220 16,995	134,088 17,049
Amortization of right of use asset (Note 7)	47,516	23,180
Accretion of debt discount on convertible debentures and non-cash interest (Notes 7 and 9) Stock-based compensation (Note 12)	128,229 820,538	108,831 776,783
	(2,896,922)	(2,407,834)
Net change in non-cash working capital accounts:  Prepaid and other current assets	(465,106)	586,983
Accounts payable and accrued liabilities	882,528	(194,610)
Cash flows from operating activities	(2,479,500)	(2,015,461)
INVESTING ACTIVITIES		
Receivable from the sale of discontinued operations (Note 3) Purchase of property and equipment (Note 5)	<u>-</u> (123,564)	13,000,000 (188,082)
Cash flows from investing activities	(123,564)	12,811,918
FINANCING ACTIVITIES		
Issue of common shares, net share issue costs (Note 10) Payment of lease liability (Note 7)	19,150,387 (58,720)	162,258 (28,325)
Cash flows from financing activities	19,091,667	133,933
EFFECT OF EXCHANGE RATE CHANGES ON CASH	110,758	(30,964)
NET CHANGE IN CASH AND CASH EQUIVALENTS	16,599,361	10,899,426
CASH AND CASH EQUIVALENTS, beginning of period	6,872,894	1,428,129
CASH AND CASH EQUIVALENTS, end of period	\$ 23,472,255	\$ 12,327,555

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

#### 1. DESCRIPTION OF BUSINESS

POET Technologies Inc. is incorporated in the Province of Ontario. POET Technologies Inc. and its subsidiaries (the "Company") design and develop the POET Optical Interposer and Photonic Integrated Circuits for the data centre and tele-communications markets. The Company's head office is located at 120 Eglinton Avenue East, Suite 1107, Toronto, Ontario, Canada M4P 1E2. These condensed unaudited consolidated financial statements of the Company were approved by the Board of Directors of the Company on May 27, 2021.

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

These condensed unaudited consolidated financial statements of the Company and its subsidiaries were prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB").

These condensed unaudited consolidated financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated audited financial statements for the year ended December 31, 2020.

The preparation of financial statements in accordance with International Accounting Standards ("IAS") 34 Interim Financial Reporting, requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed below:

#### Basis of presentation

These consolidated financial statements include the accounts of POET Technologies Inc. and its subsidiaries; ODIS Inc. ("ODIS"), Opel Solar Inc. ("OPEL"), BB Photonics Inc.,("BB Photonics"), POET Technologies Pte Ltd. ("PTS") and POET Optoelectronics Shenzhen Co. Ltd. ("POET Shenzhen"). All intercompany balances and transactions have been eliminated on consolidation.

### Foreign currency translation

These condensed unaudited consolidated financial statements are presented in U.S. dollars ("USD"), which is the Company's presentation currency.

Items included in the financial statements of each of the Company's subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statement of operations and deficit.

Assets and liabilities of entities with functional currencies other than U.S. dollars are translated into the presentation currency at the year end rates of exchange, and the results of their operations are translated at average rates of exchange for the year. The resulting translation adjustments are included in accumulated other comprehensive loss in shareholders' equity. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive loss. Elements of equity are translated at historical rates.

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

#### **Financial Instruments**

IFRS 9 introduced new classification and measurement models for financial assets. The investment classifications held-to-maturity and available-for-sale are no longer used and financial assets at fair value through other comprehensive income ("FVTOCI") were introduced. Financial assets held with an objective to hold assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest are measured at amortised cost using the effective interest method. Debt investments held with an objective to hold both assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest as well as selling the asset on the basis of fair value are measured at FVTOCI. All other financial assets are classified and measured at fair value through profit or loss ("FVTPL"). Financial liabilities are classified as either FVTPL or other financial liabilities, and the portion of the change in fair value that relates to the Company's credit risk is presented in other comprehensive income (loss). Instruments classified as FVTPL are measured at fair value with unrealized gains and losses recognized in net income (loss). Other financial liabilities are subsequently measured at amortised cost using the effective interest method.

Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL, are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in consolidated net income (loss).

#### Financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability.

# Financial liabilities

A financial liability is derecognized from the balance sheet when it is extinguished, that is, when the obligation specified in the contract is either discharged, cancelled or expires. Where there has been an exchange between an existing borrower and lender of debt instruments with substantially different terms, or there has been a substantial modification of the terms of an existing financial liability, this transaction is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. A gain or loss from extinguishment of the original financial liability is recognized in profit or loss.

The Company's financial instruments include cash and cash equivalents, receivable from the sale of discontinued operations, accounts payable and accrued liabilities.

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

# 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The following table outlines the classification of financial instruments under IFRS 9:

#### **Financial Assets**

Cash and cash equivalents

Short-term investments

Amortized cost

Amortized cost

#### **Financial Liabilities**

Accounts payable and accrued liabilities

Convertible debentures

Covid-19 government support loans

Amortized cost

Amortized cost

Convertible debentures are accounted for as a compound financial instrument with a debt component and a separate equity component. The debt component of these compound financial instruments is measured at fair value on initial recognition by discounting the stream of future interest and principal payments at the rate of interest prevailing at the date of issue for instruments of similar term and risk. The debt component is subsequently deducted from the total carrying value of the compound instrument to derive the equity component. The debt component is subsequently measured at amortized cost using the effective interest rate method. Interest expense based on the coupon rate of the debenture and the accretion of the liability component to the amount that will be payable on redemption are recognized through profit or loss as a finance cost.

# Cash and cash equivalents

Cash and cash equivalents consist of cash in current accounts of \$3,491,360 (2020 - \$722,894) and funds invested in US and Canadian Term Deposits of \$19,980,895 (2020 - \$6,150,000) earning interest at 1.31% and maturing in less than 90 days.

Cash and cash equivalents include restricted funds of \$141,978 (2020 - \$184,569) which serves as a bank guarantee for the purchase of certain equipment. The bank guarantee is reduced on a monthly basis by \$14,197 which is the amount paid monthly in settlement of the outstanding balance on the equipment.

### Property and equipment

Property and equipment are recorded at cost. Depreciation is calculated based on the estimated useful life of the asset using the following method and useful lives:

Machinery and equipment Straight Line, 5 years

Leasehold improvements Straight Line, 5 years or life of the lease, whichever is less

Office equipment Straight Line, 3 - 5 years

# Patents and licenses

Patents and licenses are recorded at cost and amortized on a straight line basis over 12 years. Ongoing maintenance costs are expensed as incurred.

#### Impairment of long-lived assets

The Company's tangible and intangible assets are reviewed for indications of impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. An assessment is made at each reporting date whether there is any indication that an asset may be impaired.

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

An impairment loss is recognized when the carrying amount of an asset exceeds its recoverable amount. Impairment losses are recognized in profit and loss for the year. The recoverable amount is the greater of the asset's fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit ("CGU") to which the asset belongs.

An impairment loss is reversed if there is an indication that there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

# **Revenue recognition**

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognizes revenue when it transfers control over a product or service to a customer.

# Sale of goods

Revenue from the sale of goods is recognized, net of discounts and customer rebates, at the point in time the transfer of control of the related products has taken place as specified in the sales contract and collectability is reasonably assured.

#### Service revenue

The Company provides contract services, primarily in the form of non-recurring revenue ("NRE") where control is passed to the customer over time. The contracts generally provide agreed upon milestones for customer payment which include but are not limited to the delivery of sample products, design reports and test reports. The customer makes payment when it has approved the delivery of the milestone. The Company must determine if the contract is made up of a series of independent performance obligations or a single performance obligation. Where NRE contracts contain multiple performance obligations for which a standalone transaction price can be assessed, revenue is recognized as each performance obligation is satisfied. Where NRE contracts contain a single performance obligation to be settled over time, revenue is recognized progressively based on the output method.

#### Other income

#### Interest income

Interest income on cash is recognized as earned using the effective interest method.

# Wage subsidies

Wages subsidies received from the Singaporean government are netted against payroll costs on the consolidated statements of operations and deficit.

# Intangible assets

### Research and development costs

Research costs are expensed in the year incurred. Development costs are also expensed in the year incurred unless the Company believes a development project meets IFRS criteria as set out in IAS 38, *Intangible Assets*, for deferral and amortization. IAS 38 requires all research costs be charged to expense while development costs are capitalised only after technical and commercial feasibility of the asset for sale or use have been established. This means that the entity must intend and be able to complete the intangible asset and either use it or sell it and be able to demonstrate how the asset will generate future economic benefits. Development costs are tested for impairment whenever events or changes indicate that its carrying amount may not be recoverable.

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in US Dollars)

# 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

### Stock-based compensation

Stock options and warrants awarded to non employees are measured using the fair value of the goods or services received unless that fair value cannot be estimated reliably, in which case measurement is based on the fair value of the stock options. Stock options and warrants awarded to employees are accounted for using the fair value method. The fair value of such stock options and warrants granted is recognized as an expense on a proportionate basis consistent with the vesting features of each tranche of the grant. The fair value is calculated using the Black-Scholes option pricing model with assumptions applicable at the date of grant.

### Loss per share

Basic loss per share, net of taxes is calculated by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period after giving effect to potentially dilutive financial instruments. The dilutive effect of stock options and warrants is determined using the treasury stock method.

# **Joint Venture**

A joint arrangement is an arrangement among two or more parties where the parties are bound by a contractual arrangement and the contractual arrangement gives the parties joint control of the arrangement. A joint venture is a form of joint arrangement where an entity is independently formed and the parties jointly have rights to the net assets of the arrangement and therefore account for their interests under the equity method.

#### 3. RECEIVABLE FROM THE SALE OF DISCONTINUED OPERATIONS

On November 8, 2019, the Company sold 100% of the issued and outstanding shares of DenseLight for \$26,000,000. The Company received \$8,000,000 upon the consummation of the sale with the remaining \$18,000,000 expected over three tranche payments in 2020. Payments received in the first quarter were as follows: \$4,750,000 received on February 14, 2020 and \$8,250,000 received on March 30, 2020.

The Company received payments of \$1,500,000 and \$1,000,000 on June 29, 2020 and July 3, 2020 respectively. After taking into consideration the length of time it had taken the Buyer to make the foregoing payments and the Company's expectations regarding the likelihood of receiving an additional payment, the Company determined that it was in its best interest to accept partial payments as final payment on the Company's receivable. As a result, the Company recognized a credit loss of \$2,500,000 during the year ended December 31, 2020.

# 4. PREPAIDS AND OTHER CURRENT ASSETS

The following table reflects the details of prepaids and other current assets:

	<b>March 31</b> , De <b>2021</b>	cember 31, 2020
Sales tax recoverable and other current assets Prepaid expenses Equipment deposit	\$ 286,292 \$ 39,589 766,135	122,353 496,364 -
	\$ 1,092,016 \$	618,717

5.

6.

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

Balance, January 1, 2020 \$ 764,342 \$ - \$ 2,873,255 \$ 85,233 \$ 3,722,830			uipment not L n service imp	easehold M provements		Office equipment	Total	
Additions     888,726     68,961     \$25,685     38,416     1,521,788       Disposals     (897,727)     -     -     -       Reclassification     (519,366)     -     516,111     3,255       Effect of changes in foreign exchange rates     (8,828)     2,967     79,606     1,281     75,026       Balance, December 31, 2020     227,147     71,928     3,994,657     128,185     4,421,917       Additions     -     -     119,612     3,952     123,564       Reclassification     (28,197)     -     28,197     -       Effect of changes in foreign exchange rates     (3,922)     (1,236)     (57,234)     (602)     (62,994)       Balance, March 31, 2021     195,028     70,692     4,085,232     131,535     4,482,487       Accumulated Depreciation       Balance, January 1, 2020     -     -     511,806     67,964     579,770       Depreciation of the period     -     3,535     181,252     34,433     18,820       Effect on changes in foreign exchange rates     -     10,777     1,146,014     79,372     12,351,633       Depreciation for the period     -     3,535     181,252     34,33     188,220       Effect of changes in foreign exchange rates <t< th=""><th>Cost</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<>	Cost							
Disposals		\$		- \$				
Reclassification	Additions			68,961	525,685	38,416		
Effect of changes in foreign exchange rates (8,828) 2,967 79,606 1,281 75,026 Balance, December 31, 2020 227,147 71,928 3,994,657 128,185 4,421,917 Additions (28,197) - 281,197 - 281,197 (602) 123,564 (72,194)	Disposals			-	-		(897,727)	
Balance, December 31, 2020 227,147 71,928 3,994,657 128,185 4,421,917 Additions			(519,366)	-	516,111	3,255	-	
Additions Reclassification (28, 197) - 28, 197 Effect of changes in foreign exchange rates (3,922) (1,236) (57,234) (602) (62,994)  Balance, March 31, 2021 195.028 70.692 4,085,232 131,535 4,482,487  Accumulated Depreciation Balance, January 1, 2020 511,806 67,964 579,770 Depreciation - 10,332 609,803 11,128 631,263 Effect on changes in foreign exchange rates - 445 24,405 280 25,130  Belance, December 31, 2020 - 10,777 1,146,014 79,372 1,236,163 Depreciation For the period - 3,535 181,252 3,433 188,220 Depreciation For the period - 3,535 181,252 3,433 188,220 Effect of changes in foreign exchange rates - (225) (12,429) (113) (12,767)  Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, December 31, 2020 and March 31, 2021 837,102  Accumulated Depreciation Balance, January 1, 2020 32,643 Amortization 415,2021 415,420  Carrying Amounts Balance, December 31, 2020 398,425 4Anortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts	Effect of changes in foreign exchange rates		(8,828)	2,967	79,606	1,281	75,026	
Additions Reclassification (28, 197) - 28, 197 6 Effect of changes in foreign exchange rates (3,922) (1,236) (67,234) (602) (62,994)  Balance, March 31, 2021 195.028 70.692 4,085,232 131,535 4,482,487  Accumulated Depreciation Balance, January 1, 2020 511,806 67,964 579,770 Depreciation - 10,332 609,803 11,128 631,263 Effect on changes in foreign exchange rates - 445 24,405 280 25,130  Depreciation Freign exchange rates - 445 24,405 280 25,130  Depreciation for the period - 10,777 1,146,014 79,372 1,236,163 Depreciation for the period - 3,535 181,252 3,433 188,220 Effect of changes in foreign exchange rates - (225) (12,429) (113) (12,767)  Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, December 31, 2020 and March 31, 2021 \$ 32,643  Accumulated Depreciation Balance, January 1, 2020 322,643  Anortization during the period 16,995  Balance, December 31, 2020 398,425  Annortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts	Balance, December 31, 2020		227,147	71,928	3,994,657	128,185	4,421,917	
Reclassification (28,197) - 28,197			-	-	119,612	3,952		
Effect of changes in foreign exchange rates  (3,922) (1,236) (57,234) (602) (62,994)  Balance, March 31, 2021 195,028 70,692 4,085,232 131,535 4,482,487  Accumulated Depreciation  Balance, January 1, 2020 511,806 67,964 579,770  Depreciation - 10,332 609,803 11,128 631,263  Effect on changes in foreign exchange rates - 445 24,405 280 25,130  Balance, December 31, 2020 - 10,777 1,146,014 79,372 1,236,163  Depreciation for the period - 3,535 181,252 3,433 188,220  Effect of changes in foreign exchange rates - (225) (12,429) (113) (12,767)  Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts  At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost  Balance, January 1, 2020 \$ 3785,027  Additions  Accumulated Depreciation  Balance, January 1, 2020 332,643  Amortization during the period 16,995  Balance, December 31, 2020 398,425  Annortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts	Reclassification		(28, 197)	_	28,197	-	=	
Accumulated Depreciation Balance, January 1, 2020	Effect of changes in foreign exchange rates			(1,236)	(57,234)	(602)	(62,994)	
Balance, January 1, 2020	Balance, March 31, 2021		195,028	70,692	4,085,232	131,535	4,482,487	
Balance, January 1, 2020	Accumulated Depreciation							
Effect on changes in foreign exchange rates - 445 24,405 280 25,130  Balance, December 31, 2020 - 10,777 1,146,014 79,372 1,236,163 Depreciation for the period - 3,535 181,252 3,433 188,220 Effect of changes in foreign exchange rates - (225) (12,429) (113) (12,767)  Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027 Additions \$ 52,075  Balance, December 31, 2020 and March 31, 2021 \$ 837,102  Accumulated Depreciation Balance, January 1, 2020 322,643 Amortization 65,782  Balance, December 31, 2020 398,425 Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts	Balance, January 1, 2020		_	-	511,806	67,964	579,770	
Effect on changes in foreign exchange rates - 445 24,405 280 25,130  Balance, December 31, 2020 - 10,777 1,146,014 79,372 1,236,163 Depreciation for the period - 3,535 181,252 3,433 188,220  Effect of changes in foreign exchange rates - (225) (12,429) (113) (12,767)  Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027 Additions \$ 52,075  Balance, December 31, 2020 and March 31, 2021 \$ 837,102  Accumulated Depreciation Balance, January 1, 2020 \$ 32,643 Amortization \$ 65,782  Balance, December 31, 2020 \$ 398,425 Amortization during the period \$ 415,420  Carrying Amounts	Depreciation		-	10,332	609,803			
Balance, December 31, 2020 - 10,777 1,146,014 79,372 1,236,163 Depreciation for the period - 3,535 181,252 3,433 188,220 Effect of changes in foreign exchange rates - (225) (12,429) (113) (12,767)  Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027 52,075  Balance, December 31, 2020 and March 31, 2021 837,102  Accumulated Depreciation Balance, January 1, 2020 32,643 Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts			-					
Depreciation for the period - 3,535 181,252 3,433 188,220 Effect of changes in foreign exchange rates - (225) (12,429) (113) (12,767)  Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027 52,075  Balance, December 31, 2020 and March 31, 2021 837,102  Accumulated Depreciation Balance, January 1, 2020 32,643 Amortization 65,782  Balance, December 31, 2020 398,425 Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts				10 777	1 140 014	70.070		
Effect of changes in foreign exchange rates - (225) (12,429) (113) (12,767)  Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027 52,075  Balance, December 31, 2020 and March 31, 2021 837,102  Accumulated Depreciation Balance, January 1, 2020 32,643 Amortization 465,782  Balance, December 31, 2020 398,425 Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts			-	. ,				
Balance, March 31, 2021 - 14,087 1,314,837 82,692 1,411,616  Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027 52,075  Balance, December 31, 2020 and March 31, 2021 837,102  Accumulated Depreciation Balance, January 1, 2020 32,643 Amortization 465,782  Balance, December 31, 2020 398,425 Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts			-					
Carrying Amounts At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027	Effect of changes in foreign exchange rates			(225)	(12,429)	(113)	(12,767)	
At December 31, 2020 \$ 227,147 \$ 61,151 \$ 2,848,643 \$ 48,813 \$ 3,185,754  At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027	Balance, March 31, 2021		-	14,087	1,314,837	82,692	1,411,616	
At March 31, 2021 \$ 195,028 \$ 56,605 \$ 2,770,395 \$ 48,843 \$ 3,070,871  PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027	Carrying Amounts At December 31, 2020	\$	227,147 \$	61,151 \$	2,848,643 \$	48,813	\$ 3,185,754	
PATENTS AND LICENSES  Cost Balance, January 1, 2020 \$ 785,027 52,075  Balance, December 31, 2020 and March 31, 2021 837,102  Accumulated Depreciation Balance, January 1, 2020 332,643 Amortization 65,782  Balance, December 31, 2020 398,425 Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts		r				40.042	£ 2.070.071	
Cost         Balance, January 1, 2020       \$ 785,027         Additions       52,075         Balance, December 31, 2020 and March 31, 2021       837,102         Accumulated Depreciation Balance, January 1, 2020 Amortization       332,643         Balance, December 31, 2020 Amortization during the period       398,425         Amortization during the period       16,995         Balance, March 31, 2021       415,420				,	, -, ,	-,		
Balance, January 1, 2020       \$ 785,027 52,075         Balance, December 31, 2020 and March 31, 2021       837,102         Accumulated Depreciation       332,643 43 43 43 43 443 443 443 443 443 443								
Additions 52,075  Balance, December 31, 2020 and March 31, 2021 837,102  Accumulated Depreciation Balance, January 1, 2020 332,643 Amortization 65,782  Balance, December 31, 2020 398,425 Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts								
Accumulated Depreciation         Balance, January 1, 2020       332,643         Amortization       65,782         Balance, December 31, 2020       398,425         Amortization during the period       16,995         Balance, March 31, 2021       415,420	Cost						\$ 785 027	
Balance, January 1, 2020       332,643         Amortization       65,782         Balance, December 31, 2020       398,425         Amortization during the period       16,995         Balance, March 31, 2021       415,420    Carrying Amounts	<b>Cost</b> Balance, January 1, 2020							
Balance, January 1, 2020       332,643         Amortization       65,782         Balance, December 31, 2020       398,425         Amortization during the period       16,995         Balance, March 31, 2021       415,420    Carrying Amounts	<b>Cost</b> Balance, January 1, 2020 Additions	)21					52,075	
Amortization 65,782  Balance, December 31, 2020 Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts		)21					52,075	
Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts	Cost Balance, January 1, 2020 Additions Balance, December 31, 2020 and March 31, 20	)21					52,075 837,102	
Amortization during the period 16,995  Balance, March 31, 2021 415,420  Carrying Amounts	Cost Balance, January 1, 2020 Additions Balance, December 31, 2020 and March 31, 20  Accumulated Depreciation Balance, January 1, 2020	)21					52,075 837,102 332,643	
Carrying Amounts	Cost Balance, January 1, 2020 Additions Balance, December 31, 2020 and March 31, 20  Accumulated Depreciation Balance, January 1, 2020 Amortization	)21					52,075 837,102 332,643 65,782	
	Cost Balance, January 1, 2020 Additions Balance, December 31, 2020 and March 31, 20  Accumulated Depreciation Balance, January 1, 2020 Amortization Balance, December 31, 2020	021					52,075 837,102 332,643 65,782 398,425	
At December 31, 2020 \$ 438,677	Cost Balance, January 1, 2020 Additions Balance, December 31, 2020 and March 31, 20  Accumulated Depreciation Balance, January 1, 2020 Amortization Balance, December 31, 2020 Amortization during the period	)21					52,075 837,102 332,643 65,782 398,425 16,995	
	Cost Balance, January 1, 2020 Additions Balance, December 31, 2020 and March 31, 20  Accumulated Depreciation Balance, January 1, 2020 Amortization Balance, December 31, 2020 Amortization during the period Balance, March 31, 2021	)21					52,075 837,102 332,643 65,782 398,425 16,995	
	Cost Balance, January 1, 2020 Additions Balance, December 31, 2020 and March 31, 20  Accumulated Depreciation Balance, January 1, 2020 Amortization Balance, December 31, 2020 Amortization during the period Balance, March 31, 2021  Carrying Amounts	021					52,075 837,102 332,643 65,782 398,425 16,995 415,420	

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 7. RIGHT OF USE ASSET AND LEASE LIABILITY

The Company recognizes a lease liability and right of use asset relating to commercial leases the Company has entered into since 2019. The lease liability is measured at the present value of the remaining lease payments, discounted using the Company's incremental borrowing rate of 12%.

Right of use asset	Building
Cost Balance, January 1, 2020 Additions Lease modification Effect of changes in foreign exchange rates	\$ 238,200 465,068 (47,939) (2,097)
Balance, December 31, 2020 Effect of changes in foreign exchange rates	653,232 (1,150)
Balance, March 31, 2021	\$ 652,082
Accumulated Amortization Balance, January 1, 2020 Amortization Effect of changes in foreign exchange rates	15,683 116,057 806
Balance, December 31, 2020 Amortization during the period Effect of changes in foreign exchange rates	132,546 47,516 (376)
Balance, March 31, 2021	179,686
Carrying Amounts	
At December 31, 2020	\$ 520,686
At March 31, 2021	\$ 472,396
Lease liability	
Balance, January 1, 2020 Additions Interest expense Lease payments Lease modification Effect of changes in foreign exchange rates	\$ 223,758 452,385 44,655 (144,142) (48,725) 4,066
Balance, December 31, 2020 Interest expense Lease payments Effect of changes in foreign exchange rates	531,997 18,476 (58,720) (1,078)
Balance, March 31, 2021	\$ 490,675

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

### 8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	ľ	<b>March 31</b> , Dec <b>2021</b>	ember 31, 2020
Trade payable Payroll related liabilities Accrued liabilities	\$	1,548,120 \$ 665,039 399,996	1,603,284 60,455 66,622
	\$	2,613,155 \$	1,730,361

#### 9. CONVERTIBLE DEBENTURES

#### **Convertible Debentures**

In 2019, Management approved the issuance of up to \$10.5 million of unsecured convertible debentures (the "Convertible Debentures") of the Company. The Convertible Debentures were sold in multiple tranches, on a brokered private placement basis through the Company's financial advisors, IBK Capital. In 2019, the Company closed five tranches of the private placement of the Convertible Debentures that raised gross proceeds of \$3,729,921 (CAD\$4,988,292). The Convertible Debentures, bear interest at 12% per annum, compounded annually with 1% payable at the beginning of each month and mature two years from the date of issue. The Company paid \$377,072 (CAD\$499,462) in brokerage fees and other costs related to the closing of these five tranches.

The Convertible Debentures are convertible at the option of the holders thereof into units at any time after October 31, 2019 at a conversion price of CAD\$0.40 per unit for a total 12,457,500 units of the Company. Each unit will consist of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share of the Company at a price of CAD\$0.50 per share for a period of four years from the date upon which the convertible debenture is issued. Upon completing the sale of DenseLight, holders of Convertible Debentures will have the right to cause the Company to repurchase the Convertible Debentures at face value, subject to certain restrictions. The Convertible Debentures are governed by a trust indenture between the Company and TSX Trust Company as trustee.

Insiders of the Company subscribed for 14.3% or \$535,000 (CAD\$710,000) of the Convertible Debentures, including the Company's board of directors and senior management team. Insiders of IBK Capital subscribed for 4% or \$146,000 (CAD\$200,000) of the Convertible Debentures.

IAS 32 Financial Instruments: Presentation define these debt securities as compound financial instruments made up of both a liability component and an equity component. The debt component of the Convertible Debentures were fair valued using effective discount rates ranging from 28.74% to 29.71% which the Company determined would be the interest rate of the debts without a conversion feature. The difference between the fair value of the debt component and the loan is allocated to the equity component and is included in shareholders' equity.

Because the Convertible Debentures are denominated in Canadian dollars and the conversion price is also denominated in Canadian dollars, the number of equity instruments that would be issued upon exercise of the convertible debentures are fixed. As a result, the equity component of the convertible debentures will not be periodically remeasured.

During 2021, holders of certain convertible debentures converted \$2,345,409 (2020 - \$369,545) worth of convertible debentures into 7,425,000 (2020 - 1,235,000) units of the Company.

The following table reflects the details of convertible debentures at March 31, 2021:

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 9. CONVERTIBLE DEBENTURES (Continued)

Convertible Debentures	Loan	Equi	ty C	Component	A	ccretion D	ebt (	Component
Issued May 3, 2019 (net of issue costs) Issued June 3, 2019 (net of issue costs) Issued August 2, 2019 (net of issue costs) Issued September 19, 2019 (net of issue costs) Effect of foreign exchange rate changes	\$ 177,74 470,75 246,77 122,96	4 2	\$	(32,936) (88,706) (47,390) (23,019)	\$	63,560 132,385 65,878 28,448	\$	208,365 514,433 265,260 128,394 53,060
Balance March 31, 2021	\$ 1,018,23	2	\$	(192,051)	\$	290,271	\$	1,169,512

The following table reflects the details of convertible debentures at December 31, 2020:

Convertible Debentures	Loan	Εqι	ity (	Component	Α	ccretion D	ebt	Component
Issued April 3, 2019 (net of issue costs) Issued May 3, 2019 (net of issue costs) Issued June 3, 2019 (net of issue costs) Issued August 2, 2019 (net of issue costs) Issued September 19, 2019 (net of issue costs) Effect of foreign exchange rate changes	\$ 1,293,519 806,899 496,999 290,369 122,969	3 5 5	\$	(242,004) (151,842) (93,278) (54,978) (23,019)	\$	338,988 218,159 117,481 62,683 22,905	\$	1,390,503 873,210 521,198 298,070 122,851 135,414
Balance December 31, 2020	\$ 3,010,73	7	\$	(565,121)	\$	760,216	\$	3,341,246

# 10. SHARE CAPITAL

(a) AUTHORIZED
Unlimited number of common shares
One special voting share

# (b) COMMON SHARES ISSUED

	Number of	
	Shares	Amount
Balance, January 1, 2020	288,363,553	\$ 112,144,172
Issued on the conversion of convertible debentures	1,235,000	369,545
Fair value of warrants issued on conversion of convertible debentures	-,,	(146,858)
Exercise of warrants issued in conjunction with debt financing	942,448	221,620
Shares issued to settle accounts payable	30,268	13,011
Funds from the exercise of stock options	3,302,835	794,808
Fair value of stock options exercised	<del>-</del>	768,356
Funds from the exercise of warrants and compensation warrants	744,000	293,642
Fair value of warrants and compensation warrants exercised	=	127,964
Balance, December 31, 2020	294,618,104	114,586,260
Funds from the exercise of stock options	7,192,243	2,192,936
Fair value of stock options exercised	-	1,870,261
Issued on the conversion of convertible debentures (Note 9)	7,425,000	2,345,409
Fair value of warrants issued upon conversion of convertible debentures	-	(819,345)
Funds from the exercise of warrants	15,319,384	6,284,890
Fair value of warrants exercised	=	2,611,206
Funds from Common shares issued on privale placement	17,647,200	11,815,595
Fair value of warrants issued on private placement	-	(3,766,007)
Share issue costs	=	(1,143,034)
Fair value of broker warrants issued as share issue costs	-	(288,197)
Balance, March 31, 2021	342,201,931	\$ 135,689,974

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 10. SHARE CAPITAL (Continued)

On February 11, 2021, the Company completed a brokered private placement offering of 17,647,200 units at a price of \$0.67 (CAD\$0.85) per unit for gross proceeds of \$11,815,595 (CAD\$15,000,120). Each unit consists of one common share and one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of \$0.90 (CAD\$1.15) per share until February 11, 2023. At any time after June 12, 2021, the Company reserves the right to accelerate the expiry of the warrants if the Company's average stock price exceeds \$1.81 (CAD\$2.30) for a period of 10 consecutive trading days. The broker was paid a cash commission of \$708,667 (CAD\$900,007) equating to 6% of the gross proceeds and received 1,058,832 broker warrants. Each broker warrant is exercisable into one common share of the Company at a price of \$0.67 (CAD\$0.85) per broker warrant until February 11, 2023. The Company incurred additional share issuance costs of \$434,367 directly related to the private placement and warrant exercises.

The fair value of the share purchase warrants and broker warrants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%, risk-free interest rate of 0.19%, volatility of 75.26%, and estimated life of 2 years. The estimated fair value assigned to the warrants and broker warrants was \$3,766,007 and \$288,197, respectively.

### 11. WARRANTS AND COMPENSATION OPTIONS

The following table reflects the continuity of warrants and compensation options:

	Avera	storical ge Exercise Price Cor	Number of Warrants/ npensation option	Historical ons Fair value
Balance, January 1, 2020 Fair value of warrants issued on conversion of	\$	0.43	49,539,792	\$ 8,525,358
convertible debentures (Note 9)  Fair value of expired compensation options issued to brokers  Fair value related to the exercise of warrants issued as cost		0.38 0.43	1,235,000 (1,505,442)	146,858 (479,204)
of debt financing <sup>(1)</sup> Fair value of expired warrants issued on public offering Historical fair value assigned to warrants exercised		0.27 0.58 0.39	(3,289,500) (12,545,350) (744,000)	(221,620) (2,286,426) (127,964)
Balance, December 31, 2020 Fair value of warrant issued on private placement Fair value of broker warrants issued on private placement Fair value of warrants issued on conversion of		0.39 0.90 0.67	32,690,500 17,647,200 1,058,832	5,557,002 3,766,007 288,197
convertible debentures (Notes 9) Historical fair value assigned to warrants exercised		0.38 0.39	7,425,000 (15,319,384)	819,345 (2,611,206)
Balance, March 31, 2021	\$	0.60	43,502,148	\$ 7,819,345

<sup>(1)</sup> These warrants had a cashless exercise feature. The warrant holder utilized the cashless exercise feature to exercise the warrants, which resulted in the Company issuing 942,448 common shares to the warrant holders.

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

### 12. STOCK OPTIONS AND CONTRIBUTED SURPLUS

### **Stock Options**

On August 26, 2020, shareholders of the Company approved amendments to the Company's fixed 20% stock option plan (as amended, previously referred to as the "2018 plan", now referred to as the "2020 Plan"). Under the 2020 Plan, the board of directors may grant options to acquire common shares of the Company to qualified directors, officers, employees and consultants. The 2020 Plan provides that the number of common shares issuable pursuant to options granted under the 2020 Plan and pursuant to other previously granted options is limited to 58,538,554 (the "Number Reserved"). Any subsequent increase in the Number Reserved must be approved by shareholders of the Company and cannot, at the time of the increase, exceed 20% of the number of issued and outstanding shares. The stock options vest in accordance with the policies determined by the Board of Directors from time to time consistent with the provisions of the 2020 Plan which grants discretion to the Board of Directors.

Stock option transactions and the number of stock options outstanding were as follows:

	Weig Number of Options	Historical ghted average Exercise Price
Balance, January 1, 2020 Expired/cancelled Exercised Granted	53,260,338 \$ (8,287,937) (3,302,835) 9,474,926	0.43 1.02 0.24 0.36
Balance, December 31, 2020 Exercised Granted	51,144,492 (7,192,243) 1,450,000	0.33 0.29 0.64
Balance, March 31, 2021	45,402,249 \$	0.35

During the three months ended March 31, 2021, the Company granted 1,450,000 (three months ended March 31, 2020 - 2,335,488) stock options to employees and consultants of the Company to purchase common shares at an average price of \$0.64 (three months ended March 31, 2020 - \$0.25) per share.

During the three months ended March 31, 2021, the Company recorded stock-based compensation of \$820,538 (three months ended March 31, 2020 - \$776,783) relating to stock options that vested during the period.

The stock options granted were valued using the Black-Scholes option pricing model using the following assumptions:

Three Months Ended March 31,	2021	2020
Weighted average exercise price	\$0.64	\$0.25
Weighted average risk-free interest rate	0.80%	0.92 - 1.52%
Weighted average dividend yield	0%	0%
Weighted average volatility	94.03%	94.96%
Weighted average estimated life	10 years	10 years
Weighted average share price	\$0.64	\$0.25
Share price on the various grant dates:	\$0.64	\$0.22- \$0.28
Weighted average fair value	\$0.55	\$0.19

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 12. STOCK OPTIONS AND CONTRIBUTED SURPLUS (Continued)

The underlying expected volatility was determined by reference to the Company's historical share price movements, its dividend policy and dividend yield and past experience relating to the expected life of granted stock options.

The weighted average remaining contractual life and weighted average exercise price of options outstanding and of options exercisable as at March 31, 2021 are as follows:

	Options Ou	ıtst	anding		Options Exercisable					
Exercise Range	Number Outstanding		Historical Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (years)	Number Exercisable	W A E	listorical /eighted .verage xercise Price			
\$0.11 - \$0.25	8,658,125	\$	0.22	6.92	6,773,750	\$	0.22			
\$0.26 - \$0.37	9,676,416	\$	0.26	8.15	4,094,541	\$	0.26			
\$0.38 - \$0.92	27,067,708	\$	0.38	7.94	13,058,050	\$	0.38			
	45,402,249	\$	0.35	7.79	23,926,341	\$	0.35			

### 13. LOSS PER SHARE

		Three Months Ended March 31,			
		2021	2020		
Numerator Net loss	\$	(4,098,420) \$	(3,467,765)		
Denominator					
Weighted average number of common shares outstanding - basic and diluted	;	320,755,967	289,386,778		
Basic and diluted loss per share	\$	(0.01) \$	(0.01)		

The effect of common share purchase options, warrants and compensation options on the net loss in 2021 and 2020 is not reflected as they are anti-dilutive.

# 14. COMMITMENTS AND CONTINGENCIES

The Company has operating leases on four facilities; head office located in Toronto, Canada, design and testing operations located in Allentown, Pennsylvania (formerly in San Jose, California) and operating facilities located in Singapore and China. The Company's design and testing operations terminated a lease on January 31, 2020. A new lease was initiated on April 1, 2020 and expires on March 31, 2025. The lease on the Company's operating facilities in Singapore was initiated on November 1, 2019 and expires April 30, 2022. The lease on the Company's operating facilities in China was initiated in November 19, 2020 and expires on November 18, 2023. As at March 31, 2021, the Company's head office was on a month to month lease term.

Remaining minimum annual rental payments to the lease expiration dates are as follows:	
April 1, 2021 to December 31, 2021	\$ 179,213
2022 and beyond	441,450
	\$ 620,663

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

#### 15. RELATED PARTY TRANSACTIONS

Compensation to key management personnel were as follows:

		Month Marc	ns Ended h 31,
	2021		2020
Salaries	\$ 583,501	\$	418,475
Share-based payments (1)	440,409		484,842
Total	\$ 1,023,910	\$	903,317

<sup>(1)</sup> Share-based payments are the fair value of options granted to key management personnel and expensed during the various periods as calculated using the Black-Scholes model.

All transactions with related parties have occurred in the normal course of operations and are measured at the exchange amounts, which are the amounts of consideration established and agreed to by the related parties.

### 16. SEGMENT INFORMATION

The Company and its subsidiaries operate in a single segment; the design, manufacture and sale of semi-conductor products and services for commercial applications. The Company's operating and reporting segment reflects the management reporting structure of the organization and the manner in which the chief operating decision maker regularly assesses information for decision making purposes, including the allocation of resources. A summary of the Company's operations is below:

### **OPEL, ODIS, POET Shenzhen and PTS**

OPEL, ODIS, POET Shenzhen and PTS are the developers of the POET platform semiconductor process IP for monolithic fabrication of integrated circuit devices containing both electronic and optical elements on a single die.

#### **BB Photonics**

BB Photonics develops photonic integrated components for the datacom and telecom markets utilizing embedded dielectric technology that enables the low-cost integration of active and passive devices into photonic integrated circuits.

On a consolidated basis, the Company operates geographically in China and Singapore (collectively "Asia"), the United States and Canada. Geographical information is as follows:

2021
------

As of March 31,	Asia	US	S Canada		Consolidated		
Current assets	\$ 411,921	\$ 434,641	\$	23,717,709	\$	24,564,271	
Property and equipment	2,862,038	208,833		-		3,070,871	
Patents and licenses	-	421,682		-		421,682	
Right of use assets	254,849	217,547		-		472,396	
Total Assets	\$ 3,528,808	\$ 1,282,703	\$	23,717,709	\$	28,529,220	

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 16. SEGMENT INFORMATION (Continued)

For the Three Months Ended March 31,		Asia	US	Canada	Consolidated		
Selling, marketing and							
administration	\$	338,045	\$ 1,557,321	\$ 433,066	\$	2,328,432	
Research and development		910,912	377,512	254,294		1,542,718	
Interest expense Other income, including		10,318	8,158	216,103		234,579	
Interest		-	-	(7,309)		(7,309)	
Net loss	\$	1,259,275	\$ 1,942,991	\$ 896,154	\$	4,098,420	

As of December 31,	Asia		US	Canada	Consolidated		
Current assets	\$	304,450	\$ 69,874	\$ 7,117,287	\$	7,491,611	
Property and equipment		2,982,496	203,258	-		3,185,754	
Patents and licenses		-	438,677	=		438,677	
Right of use assets		289,542	231,144	-		520,686	
Total Assets	\$	3,576,488	\$ 942,953	\$ 7,117,287	\$	11,636,728	

For the Three Months Ended March 31,	Asia	US	US Canada		Consolidated		
Selling, marketing and administration \$ Research and development Interest Other income, including interest	282,405 498,041 6,954	\$ 1,185,985 284,445 - -	\$	240,482 761,085 209,730 (1,362)	\$ 1,708,872 1,543,571 216,684 (1,362)		
Net loss \$	-	\$ 1,470,430	\$	1,209,935	\$ 3,467,765		

# 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company's financial instruments consist of cash and cash equivalents, convertible debentures, covid-19 government support loans and accounts payable and accrued liabilities. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest risk arising from these financial instruments. The Company estimates that carrying value of these instruments approximates fair value due to their short term nature.

The Company has classified financial assets and (liabilities) as follows:

	I	March 31, 2021	December 31, 2020
Cash and cash equivalents, measured at amortized cost:			
Cash and cash equivalents	\$	23,472,255	\$ 6,872,894
Other liabilities, measured at amortized cost:			
Accounts payable and accrued liabilities	\$	(2,613,155)	\$ (1,730,361)
Convertible debentures			\$ (3,341,246)
Covid-19 government support loans	\$	(218,587)	

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)

# **Exchange Rate Risk**

The functional currency of each of the entities included in the accompanying consolidated financial statements is the local currency where the entity is domiciled. Functional currencies include the Chinese Yuan, US, Singapore, and Canadian dollar. Most transactions within the entities are conducted in functional currencies. As such, none of the entities included in the consolidated financial statements engage in hedging activities. The Company is exposed to a foreign currency risk with the Chinese Yuan, Canadian and Singapore dollar. A 10% change in the Chinese Yuan, Canadian and Singapore dollar would increase or decrease other comprehensive loss or discontinued operations by \$2,100,000.

# **Liquidity Risk**

The Company currently does not maintain credit facilities. The Company's existing cash and cash resources are considered sufficient to fund operating and investing activities beyond one year from the issuance of these unaudited condensed consolidated financial statements.

### 18. CAPITAL MANAGEMENT

In the management of capital, the Company includes shareholders' equity (excluding accumulated other comprehensive loss and deficit) and cash and cash equivalents. The components of capital on March 31, 2021 were:

Cash and cash equivalents \$ 23,472,255 Shareholders' equity \$ 187,423,152

The Company's objective in managing capital is to ensure that financial flexibility is present to increase shareholder value through growth and responding to changes in economic and/or market conditions; to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business and to safeguard the Company's ability to obtain financing should the need arise.

In maintaining its capital, the Company has a strict investment policy which includes investing its surplus capital only in highly liquid, highly rated financial instruments. The Company reviews its capital management approach on an ongoing basis.

### 19. EXPENSES

Research and development costs can be analysed as follows:

	Three Months Ended March 31,			
		2021		2020
Wages and benefits	\$	582,472	\$	387,382
Subcontract fees		508,075		875,622
Stock-based compensation		202,934		123,827
Supplies		249,237		156,740
	\$	1,542,718	\$	1,543,571
Stock-based compensation Wages and benefits	\$	617,604 816,012	\$	652.956
General expenses Professional fees Depreciation and amortization Rent and facility costs		344,347 284,105 252,731 13,633		543,571 197,232 125,001 174,317 15,795

# NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

# 20. COVID-19 GOVERNMENT SUPPORT LOANS (Continued)

In March 2020, the United States Congress passed the Paycheck Protection Program ("PPP"), authorizing loans to small businesses for use in paying employees that they continue to employ throughout the COVID-19 pandemic and for rent, utilities and interest on mortgages. Loans obtained through the PPP are eligible to be forgiven as long as the proceeds are used for qualifying purposes and certain other conditions are met. On May 3, 2020, the Company received a loan in the amount of \$186,747 through the PPP. Management expects that the entire loan will be used for payroll, utilities and interest; therefore, management anticipates that the loan will be substantially forgiven. To the extent it is not forgiven, the Company would be required to repay that portion at an interest rate of 1% over a period of two years, beginning July 2021 with a final installment in May 2022. The Company may prepay the PPP loan at any time prior to maturity with no penalty.

On April 9, 2020, the Canadian government launched the Canada Emergency Business Account ("CEBA") which is intended to support businesses during COVID-19 by providing interest free financing of up to \$31,840 (CA\$40,000) until December 31, 2022. If 75% of the loan is repaid by December 31, 2022, the loan recipient will be eligible for a loan forgiveness of the remaining 25% of the amount loaned. On April 15, 2020, the Company received a loan in the amount of \$31,840 through the CEBA. If the loan has not been repaid by December 31, 2022, the outstanding amount will be automatically extended for an additional three years at 5% interest per annum payable monthly and maturing on December 31, 2025. The Company expects to repay 75% of the amount borrowed prior to December 31, 2022.

### 21. JOINT VENTURE

On October 20, 2020, the Company signed a Joint Venture Agreement ("JVA") establishing a joint venture company, Super Photonics Xiamen Co., Ltd ("SPX") with Xiamen Sanan Integrated Circuit Co. Ltd. ("Sanan IC") whose purpose is to design, develop, manufacture and sell 100G, 200G and 400G optical engines based on POET's proprietary Optical Interposer platform technology. SPX was registered on March 12, 2021. SPX will be subsequently capitalized through a combination of committed cash, capital equipment and intellectual property from Sanan IC and intellectual property and know-how from POET.